DK3565844T3 - Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer - Google Patents
Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer Download PDFInfo
- Publication number
- DK3565844T3 DK3565844T3 DK18704101.7T DK18704101T DK3565844T3 DK 3565844 T3 DK3565844 T3 DK 3565844T3 DK 18704101 T DK18704101 T DK 18704101T DK 3565844 T3 DK3565844 T3 DK 3565844T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- methods
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444336P | 2017-01-09 | 2017-01-09 | |
| US201762477423P | 2017-03-27 | 2017-03-27 | |
| US201762491220P | 2017-04-27 | 2017-04-27 | |
| US201762556386P | 2017-09-09 | 2017-09-09 | |
| PCT/US2018/013029 WO2018129559A1 (en) | 2017-01-09 | 2018-01-09 | Methods of treating cancer with anti-pd-1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3565844T3 true DK3565844T3 (da) | 2023-05-01 |
| DK3565844T5 DK3565844T5 (da) | 2024-09-02 |
Family
ID=61188903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18704101.7T DK3565844T5 (da) | 2017-01-09 | 2018-01-09 | Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11407830B2 (da) |
| EP (2) | EP3565844B8 (da) |
| JP (2) | JP7110206B6 (da) |
| KR (1) | KR102606252B1 (da) |
| CN (1) | CN110382545A (da) |
| AU (2) | AU2018206481B2 (da) |
| BR (1) | BR112019014187A2 (da) |
| CA (1) | CA3049440A1 (da) |
| DK (1) | DK3565844T5 (da) |
| ES (1) | ES2945745T3 (da) |
| FI (1) | FI3565844T3 (da) |
| HU (1) | HUE061842T2 (da) |
| IL (1) | IL267804B2 (da) |
| MA (1) | MA47208A (da) |
| MX (1) | MX2019008207A (da) |
| PL (1) | PL3565844T3 (da) |
| PT (1) | PT3565844T (da) |
| SG (2) | SG11201906192SA (da) |
| TW (1) | TWI767976B (da) |
| WO (1) | WO2018129559A1 (da) |
| ZA (1) | ZA201904316B (da) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE036780T2 (hu) | 2008-04-09 | 2018-07-30 | Genentech Inc | Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére |
| TW202436356A (zh) | 2016-10-11 | 2024-09-16 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| EP3666794A1 (en) | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| BR112019014187A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-pd-1 |
| US12156872B2 (en) | 2017-05-09 | 2024-12-03 | Tesaro, Inc. | Combination therapies for treating cancer |
| CA3063715A1 (en) | 2017-05-18 | 2018-11-22 | Tesaro, Inc. | Combination therapies for treating cancer |
| CA3076907A1 (en) | 2017-09-26 | 2019-04-04 | Tesaro, Inc. | Niraparib formulations |
| CN111372607A (zh) | 2017-09-30 | 2020-07-03 | 特沙诺有限公司 | 用于治疗癌症的联合疗法 |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| SG11202007590TA (en) | 2018-02-13 | 2020-09-29 | Merck Sharp & Dohme | Methods for treating cancer with anti-pd-1 antibodies |
| TWI852940B (zh) * | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
| TWI853841B (zh) | 2018-10-03 | 2024-09-01 | 美商提薩羅有限公司 | 尼拉帕尼（niraparib）鹽 |
| WO2020072796A1 (en) | 2018-10-03 | 2020-04-09 | Tesaro, Inc. | Crystalline forms of niraparib freebase |
| WO2020128908A2 (en) * | 2018-12-20 | 2020-06-25 | Medimmune, Llc | Methods for selection and expansion of t cells expressing pd-1 |
| AU2020282791A1 (en) * | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
| CA3164600A1 (en) * | 2019-12-18 | 2021-06-24 | Tesaro, Inc. | Biopharmaceutical compositions and related methods |
| EP4085908A4 (en) * | 2019-12-31 | 2024-01-17 | Fukang (Shanghai) Health Technology Co., Ltd. | PHARMACEUTICAL COMBINATION FOR TREATING TUMORS AND ITS APPLICATION |
| US20230067202A1 (en) | 2020-01-28 | 2023-03-02 | Glaxosmithkline Intellectual Property Development Limited | Combination Treatments and Uses and Methods Thereof |
| EP4060346A4 (en) * | 2020-02-18 | 2023-12-13 | Innobation Bio Co., Ltd. | COMPANION DIAGNOSTIC BIOMARKER COMPOSITION AND COMPANION DIAGNOSTIC KIT CONTAINING SAME |
| WO2021206831A1 (en) * | 2020-04-07 | 2021-10-14 | Metanoi Therapeutics, Inc. | Ethanolamine formulation for treating epithelial ovarian carcinoma |
| PH12022553181A1 (en) | 2020-05-26 | 2024-03-04 | Boehringer Ingelheim Int | Anti-pd-1 antibodies |
| IL298946A (en) * | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| WO2022025482A1 (ko) * | 2020-07-29 | 2022-02-03 | 재단법인 아산사회복지재단 | 스트렙토니그린 및 면역관문 억제제를 유효성분으로 포함하는 대장암 예방 및 치료용 조성물 |
| WO2022090529A1 (en) * | 2020-11-02 | 2022-05-05 | Ares Trading S.A. | Combination treatment of cancer |
| CN115607664A (zh) * | 2021-07-15 | 2023-01-17 | 嘉和生物药业有限公司 | 抗pd-1抗体在治疗宫颈癌中的应用 |
| WO2023076668A1 (en) * | 2021-10-29 | 2023-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for treatment of cancer |
| WO2023153763A1 (ko) * | 2022-02-08 | 2023-08-17 | 고려대학교 산학협력단 | C-met의 에피토프 및 hif1alpha의 에피토프를 포함하는 암 백신 및 이의 용도 |
| WO2024211551A1 (en) | 2023-04-06 | 2024-10-10 | Glaxosmithkline Intellectual Property (No.4) Limited | Methods for treating and monitoring cancer |
| GB202308807D0 (en) | 2023-06-13 | 2023-07-26 | Ionctura Sa | Combinations |
| WO2025040080A1 (en) * | 2023-08-21 | 2025-02-27 | Beigene Switzerland Gmbh | Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| DK0557459T3 (da) | 1990-11-13 | 1997-12-15 | Immunex Corp | Bifunktionelle, selekterbare fusionsgener |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| AU7309601A (en) | 2000-06-28 | 2002-01-08 | Genetics Inst | Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| JP3871326B2 (ja) | 2000-11-15 | 2007-01-24 | 小野薬品工業株式会社 | Ｐｄ−１欠損マウスおよびその用途 |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| JP2004533226A (ja) | 2001-04-02 | 2004-11-04 | ワイス | Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用 |
| JP4249013B2 (ja) | 2001-07-31 | 2009-04-02 | 佑 本庶 | Ｐｄ−１に対し特異性を有する物質 |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| EP2206517B1 (en) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| CN104436190A (zh) | 2005-06-08 | 2015-03-25 | 达纳-法伯癌症研究院公司 | 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物 |
| EP1907001B1 (en) | 2005-06-17 | 2015-07-15 | Merck Sharp & Dohme Corp. | Ilt3 binding molecules and uses therefor |
| WO2007100098A1 (ja) | 2006-03-03 | 2007-09-07 | Kyoto University | 細胞表面機能分子の細胞外領域多量体 |
| PL2074145T3 (pl) | 2006-10-02 | 2017-11-30 | Ac Immune S.A. | Humanizowane przeciwciało przeciw amyloidowi beta |
| CA2673870A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| EP2805945B1 (en) | 2007-01-10 | 2019-04-03 | MSD Italia S.r.l. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| BRPI0807952A2 (pt) | 2007-02-20 | 2014-06-10 | Anaptysbio Inc | Sistemas de hipermutação somática |
| MY149129A (en) | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
| CA2687377C (en) | 2007-05-30 | 2013-05-14 | Genexine Co., Ltd. | Immunoglobulin fusion proteins |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| WO2009026472A1 (en) | 2007-08-21 | 2009-02-26 | The General Hospital Corporation | Methods for inducing tolerance |
| US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
| EP2650308A3 (en) | 2007-10-05 | 2014-11-12 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| JP5989965B2 (ja) | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP2307050A4 (en) | 2008-07-04 | 2012-07-25 | Ono Pharmaceutical Co | USE OF A EFFECTIVENESS MARKER TO OPTIMIZE THE THERAPEUTIC EFFECTIVENESS OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| AU2009290543B2 (en) | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| EP2370593B1 (en) | 2008-11-28 | 2016-03-30 | Emory University | Methods for determining the efficacy of pd-1 antagonists |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| PE20121646A1 (es) * | 2009-11-04 | 2012-12-02 | Merck Sharp & Dohme | Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica |
| SG181952A1 (en) | 2009-12-29 | 2012-07-30 | Emergent Product Dev Seattle | Heterodimer binding proteins and uses thereof |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| CA2791930A1 (en) | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| US20110256135A1 (en) | 2010-03-17 | 2011-10-20 | Wolfgang Fraunhofer | Anti-nerve growth factor (ngf) antibody compositions |
| US20130035472A1 (en) | 2010-03-17 | 2013-02-07 | Anaptysbio, Inc. | Method of producing transcripts using cryptic splice sites |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| BR112013002532A2 (pt) | 2010-08-05 | 2016-05-31 | Hoffmann La Roche | proteína de fusão de citocina anti-viral do anticorpo anti-mhc |
| US20130217656A1 (en) | 2010-08-12 | 2013-08-22 | Beth Israel Deaconess Medical Center Inc | Methods and compositions for diagnosing and treating lupus |
| US20130310266A1 (en) | 2010-09-03 | 2013-11-21 | Immport Therapeutics, Inc. | Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders |
| CN107090029B (zh) | 2010-11-11 | 2021-07-13 | 港大科桥有限公司 | 可溶性 pd-1变体、融合构建体及其用途 |
| US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| CA2830806C (en) | 2011-03-31 | 2020-05-12 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| CN107519486B (zh) | 2011-06-24 | 2021-06-11 | 台北荣民总医院 | 于感染性与恶性疾病的治疗中提升免疫反应的方法 |
| EA026924B1 (ru) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
| EP3939613A1 (en) | 2011-08-11 | 2022-01-19 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for autoimmune diseases comprising pd-1 agonist |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| WO2013177102A2 (en) | 2012-05-21 | 2013-11-28 | Felder Mitchell S | Treatment of cancer by manipulating the immune system |
| WO2013174997A1 (en) | 2012-05-25 | 2013-11-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies |
| RU2689760C2 (ru) | 2012-05-31 | 2019-05-30 | Дженентек, Инк. | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов |
| KR102243062B1 (ko) | 2013-05-02 | 2021-04-21 | 아납티스바이오, 아이엔씨. | 예정된 사멸-1에 대한 항체 |
| ES2746805T3 (es) | 2013-12-12 | 2020-03-06 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| EP3114144A1 (en) * | 2014-03-05 | 2017-01-11 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| EP3122779B1 (en) | 2014-03-24 | 2019-05-22 | Cancer Research Technology Limited | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
| HUE048677T2 (hu) | 2014-06-19 | 2020-07-28 | Regeneron Pharma | Humanizált programozott sejthalál 1 génnel rendelkezõ nem-humán állatok |
| US9982053B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| US20170247455A1 (en) * | 2014-08-22 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| MA41217A (fr) | 2014-12-19 | 2017-10-24 | Advaxis Inc | Polythérapies ayant des souches de listeria recombinées |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| CA3175979A1 (en) | 2014-12-22 | 2016-06-30 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| LT3240801T (lt) | 2014-12-31 | 2021-02-25 | Checkmate Pharmaceuticals, Inc. | Kombinuota navikų imunoterapija |
| JP6313530B1 (ja) | 2015-01-16 | 2018-04-18 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | 標的化成分及びエフェクター成分を有する分子構築物 |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| CN107847589B (zh) | 2015-04-01 | 2022-03-29 | 安奈普泰斯生物有限公司 | 针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体 |
| SG11201708223QA (en) * | 2015-04-17 | 2017-11-29 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| ES2861352T3 (es) * | 2015-04-28 | 2021-10-06 | Bristol Myers Squibb Co | Tratamiento del melanoma positivo para PD-L1 utilizando un anticuerpo anti-PD-1 |
| LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| BR112019008861A2 (pt) | 2016-11-01 | 2019-07-09 | Tesaro, Inc. | anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3) |
| EP3666794A1 (en) * | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| TW201825512A (zh) * | 2016-11-29 | 2018-07-16 | 美商提薩羅有限公司 | 針對計劃性死亡-１（ｐｄ-１）之抗體 |
| SG10201913083SA (en) | 2017-01-09 | 2020-03-30 | Tesaro Inc | Methods of treating cancer with anti-tim-3 antibodies |
| BR112019014187A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-pd-1 |
| CN111372607A (zh) | 2017-09-30 | 2020-07-03 | 特沙诺有限公司 | 用于治疗癌症的联合疗法 |
| TWI852940B (zh) | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
-
2018
- 2018-01-09 BR BR112019014187-1A patent/BR112019014187A2/pt unknown
- 2018-01-09 PT PT187041017T patent/PT3565844T/pt unknown
- 2018-01-09 US US16/476,536 patent/US11407830B2/en active Active
- 2018-01-09 DK DK18704101.7T patent/DK3565844T5/da active
- 2018-01-09 AU AU2018206481A patent/AU2018206481B2/en active Active
- 2018-01-09 ES ES18704101T patent/ES2945745T3/es active Active
- 2018-01-09 WO PCT/US2018/013029 patent/WO2018129559A1/en not_active Ceased
- 2018-01-09 PL PL18704101.7T patent/PL3565844T3/pl unknown
- 2018-01-09 IL IL267804A patent/IL267804B2/en unknown
- 2018-01-09 KR KR1020197023407A patent/KR102606252B1/ko active Active
- 2018-01-09 EP EP18704101.7A patent/EP3565844B8/en active Active
- 2018-01-09 EP EP23158731.2A patent/EP4219563A3/en active Pending
- 2018-01-09 CN CN201880016132.XA patent/CN110382545A/zh active Pending
- 2018-01-09 HU HUE18704101A patent/HUE061842T2/hu unknown
- 2018-01-09 CA CA3049440A patent/CA3049440A1/en active Pending
- 2018-01-09 MX MX2019008207A patent/MX2019008207A/es unknown
- 2018-01-09 JP JP2019537103A patent/JP7110206B6/ja active Active
- 2018-01-09 SG SG11201906192SA patent/SG11201906192SA/en unknown
- 2018-01-09 MA MA047208A patent/MA47208A/fr unknown
- 2018-01-09 FI FIEP18704101.7T patent/FI3565844T3/fi active
- 2018-01-09 SG SG10201913075RA patent/SG10201913075RA/en unknown
- 2018-01-09 TW TW107100822A patent/TWI767976B/zh active
-
2019
- 2019-06-28 ZA ZA2019/04316A patent/ZA201904316B/en unknown
-
2022
- 2022-04-11 JP JP2022065095A patent/JP2022082809A/ja active Pending
- 2022-07-15 US US17/812,933 patent/US12415855B2/en active Active
-
2025
- 2025-01-30 AU AU2025200639A patent/AU2025200639A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3565844T3 (da) | Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer | |
| IL304117A (en) | Anti-pvrig antibodies and methods of use | |
| DK3455259T3 (da) | Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling | |
| DK3458478T3 (da) | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling | |
| IL259713A (en) | Anti-dr5 antibodies and methods of use thereof | |
| DK3394103T3 (da) | Kombination af anti-PD-1-antistoffer og bispecifikke anti-CD20-/anti-CD3-antistoffer til cancerbehandling | |
| DK3699198T3 (da) | Fremgangsmåder til tumorbehandling ved hjælp af bispecifikke CD3XCD20-antistoffer | |
| PL3551660T3 (pl) | Przeciwciała anty-ctla-4 i sposoby ich stosowania | |
| DK3178849T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
| EP3244926C0 (en) | TREATMENT OF CANCER WITH ANTI-LAP MONOCLONAL ANTIBODIES | |
| DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer | |
| IL255569A (en) | Methods of treating cancer using anti-ox40 antibodies | |
| DK3478286T3 (da) | Fremgangsmåder til behandling af ovariecancer | |
| HUE051700T2 (hu) | Anti-PD-1 antitestek | |
| IL286208A (en) | Humanized influenza monoclonal antibodies and methods of use thereof | |
| DK3826667T3 (da) | Claudin6-antistoffer og fremgangsmåder til behandling af kræft | |
| DK3142751T3 (da) | Anti-B7-H1- og anti-CTLA-4-antistoffer til behandling af ikke-småcellet lungecancer | |
| DK3307322T3 (da) | Humaniserede anti-cd40-antistoffer og anvendelser deraf | |
| DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| DK3810281T3 (da) | Fremgangsmåder til behandling af cancer med bispecifikke antI-CD3XMUC16-antistoffer og anti-PD-1-antistoffer | |
| DK4339615T3 (da) | Anti-PD-1-antistof til anvendelse i behandlingen af kræft | |
| DK3377516T3 (da) | Sammensætning til behandling af cancer | |
| DK3134124T3 (da) | Igf-1r-antistof-lægemiddel-konjugat og dens anvendelse til behandling af kræft | |
| DK3292153T3 (da) | Kombination af en cd30xcd16a-antistof med en anti-pd-1 antagonistisk antistof til behandling |